Longitudinal computed tomography-based delta-radiomics of visceral adipose tissue predicts infliximab secondary loss of response in Crohn’s disease patients

Figure 3 Establishment of the combined model and predictive performance of models for predicting secondary loss of response. A: The developed nomogram of combined model scaled by the proportional regression coefficient of each predictor; B and C: Receiver operating characteristic curves of the clinical model, delta-radiomics model and combined model in the training cohort (B) and the validation cohort (C). VAT: Visceral adipose tissue; SAT: Subcutaneous adipose tissue; AUC: Area under the receiver operating characteristic curve. ¹VAT/SAT volume ratio prior to infliximab treatment.